-
Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far Clin. Drug Investig. (IF 3.2) Pub Date : 2024-03-09 Upinder Kaur, Bhairav Kumar Pathak, Tharik Jalal Meerashahib, Dondapati Venkata Vamshi Krishna, Sankha Shubhra Chakrabarti
-
Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan Clin. Drug Investig. (IF 3.2) Pub Date : 2024-03-06 Teppei Hagino, Risa Hamada, Mai Yoshida, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
-
An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-22
Abstract Background and Objective Long-acting injectable antipsychotics have shown benefits over oral medications with reduced hospitalization rates and improved health-related quality of life. RBP-7000 (PERSERIS®) is a monthly risperidone formulation (90 or 120 mg) for the treatment of schizophrenia administered by subcutaneous abdominal injection. The objective of this study was to assess a higher
-
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-21
Abstract Background and Objectives Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo. Methods A
-
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C) Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-20 Christopher F. Bell, Priyanka Bobbili, Raj Desai, Daniel C. Gibbons, Myriam Drysdale, Maral DerSarkissian, Vishal Patel, Helen J. Birch, Emily J. Lloyd, Adina Zhang, Mei Sheng Duh
-
Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-20 Xiongwen Yang, Bo Yang, Dan Li, Wei Pan, Qin Tong, Lili Wang, Danjun Chen, Chengxiao Fu
-
Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-16 Felicia Y. Wang, Kevin C. McLaughlin, Michael J. Schontz, Jeremy R. DeGrado, Robert E. Dannemiller
-
Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-07
Abstract Background and Objective The relationship between hyperuricemia and mortality in patients with acute coronary syndrome (ACS) is considerably controversial. Additionally, the strategy of dual antiplatelet therapy (DAPT) has not been evaluated in patients with ACS with hyperuricemia. This study aims to evaluate the impact of hyperuricemia on the prognosis of ACS and explore the efficacy of ticagrelor
-
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System Clin. Drug Investig. (IF 3.2) Pub Date : 2024-02-01 Wenwang Lang, Lian Deng, Bei Huang, Dongmei Zhong, Gaofeng Zhang, Meijun Lu, Ming Ouyang
-
Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance Clin. Drug Investig. (IF 3.2) Pub Date : 2024-01-31 Matteo Colina, Micheline Khodeir, Roberto Rimondini, Marco Valentini, Federica Campomori, Stefania Corvaglia, Gabriele Campana
-
Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care Clin. Drug Investig. (IF 3.2) Pub Date : 2024-01-10 Toby G. D. Capstick, Sanjay Gudimetla, David S. Harris, Rachel Malone, Omar S. Usmani
-
A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate–Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis Clin. Drug Investig. (IF 3.2) Pub Date : 2024-01-09 Meenesh R. Juvekar, Gauri Kapre Vaidya, Aniruddha Majumder, Amod D. Pendharkar, Anthony Irudhayarajan, Avijit Kundu, D. Ramesh, J. Dheeraj Kumar, B. Jagannatha, Joseph Mathew, Mahesh P. Nikam, Madhuri Mehta, Neeraj Chawla, Priti Hajare, P. G. Chandre Gowda, P. V. L. N. Murthy, Suma Moni Mathew, Makarand V. Damle, Chandra Kant, Arun B. Nair, Ashok Jaiswal, Ravi T. Mehta
-
-
Antibiotic-Associated Acute Kidney Injury Among Older Adults: A Case-Crossover Study Clin. Drug Investig. (IF 3.2) Pub Date : 2024-01-03 Tichawona Chinzowu, Te-yuan Chyou, Prasad S. Nishtala
-
Association Between Antidiabetic Drugs and Delirium: A Study Based on the Adverse Drug Event Reporting Database in Japan Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-23 Yukiko Ishibashi, Rintaro Sogawa, Kenji Ogata, Ayaka Matsuoka, Haruna Yamada, Toru Murakawa-Hirachi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe
-
Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-19 Egídio Freitas, Maria João Paiva Lopes, Maria João Cruz, Diogo Sousa, Ana Clara Valente, Bruno Duarte, Laetitia Teixeira, Gilberto Rosas, Mónica Caetano, Alberto Mota, Paulo Filipe, Tiago Torres
-
Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-19 Linlin Hu, Qiuyue Sun, Lu Tang, Mingmin Cai, Wei Qian, Ting Dou, Huiping Wang, Yong Wu, Yongqiang Liu
-
Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-17
Abstract Background and Objectives Upadacitinib is an oral selective Janus kinase-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients \(\ge\) 12 years of age. In real life, upadacitinib currently represents a valid therapeutic option for patients failing available systemic therapies, in particular patients who discontinued dupilumab because of lack of efficacy
-
Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-16
Abstract Background and Objective Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and mortality, significantly affecting productivity and overall quality of life. The aim of the present study was to evaluate the cost effectiveness
-
Lecanemab: More Questions Than Answers! Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-14 Upinder Kaur, Jaideep Reddy, Ashutosh Tiwari, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti
The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer’s disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer’s disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials. However, there have been many questions raised over the clinical
-
Needle-Free Jet Injector-Assisted Triamcinolone Treatment of Keloids and Hypertrophic Scars is Effective and Well Tolerated in Children Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-13 Vazula Zulfra Bekkers, Claire Van Eijsden, Qi Yin, Albert Wolkerstorfer, Errol Prospero Prens, Martijn Bastiaan Adriaan van Doorn
-
Comparison of the Incidence of Adverse Events Between Japanese and Non-Japanese Healthy Subjects in Phase I Studies: A Systematic Review and Meta-Analysis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-12-02 Satomi Sakurai, Kazuhiro Matsui, Mamoru Narukawa
-
Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-30 Valérie Horvais, Philippe Beurrier, Vincent Cussac, Brigitte Pan-Petesch, Solène Schirr-Bonnans, Johann Rose, Sophie Bayart, Catherine Ternisien, Marc Fouassier, Marianne Sigaud, Antoine Babuty, Nicolas Drillaud, Benoît Guillet, Marc Trossaërt
-
Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-28 Mona Darwish, Rene Nunez, James M. Youakim, Philmore Robertson
-
Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-23 Wei Zhuang, Mei Lu, Ye Wu, Zhehui Chen, Minying Wang, Xudong Wang, Shaoxing Guan, Wanlong Lin
-
Clinical and Laboratory Factors Related to Seizure and Serotonin Toxicity in Tramadol Intoxication: An Egyptian Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-25 Ahmed Amin Ali, Mahmoud Mohamed Abdeshafy, Khaled Abdelkawy, Ramy M. Elsabaa, Fawzy Elbarbry
-
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA? Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-17 Wenhua Wu, Huiting Lin, Jiaqin Cai, Hong Sun, Jia Liu, Congting Hu, Xiaoxia Wei
-
Tauro-Urso-Deoxycholic Acid Trials in Amyotrophic Lateral Sclerosis: What is Achieved and What to Expect Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-16 Maria Lo Giudice, Antoniangela Cocco, Giorgio Reggiardo, Stefania Lalli, Alberto Albanese
-
Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-08 Xiaojuan Jiao, Ping Peng, Qin Zhang, Yunfeng Shen
-
Monotherapy Versus Combination Therapy in the Treatment of Painful Diabetic Neuropathy: A Systematic Review and Meta-analysis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-08 Julyana Medeiros Dantas, Mariana de Jesus Oliveira, Luciana Alves Oliveira Silva, Sávio Batista, Caroline Serafim Dagostin, Daniel Campinho Schachter
-
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-07 Kentaro Watanabe, Susumu Yamaguchi, Yoshinori Kosakai, Tetsuya Ioji, Hisamitsu Ishihara
-
Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial Clin. Drug Investig. (IF 3.2) Pub Date : 2023-11-02 Xue-Ning Li, Hong-Rong Xu, Ellen Cui, Kamilla Buchberg Petersen, Janka Ryding, Anders Ettrup, Jette Buch Østergaard, Frank Larsen
-
Use of Acitretin Among Girls and Women of Childbearing Age and Occurrence of Acitretin-Exposed Pregnancies in Germany Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-31 Jonas Reinold, Bianca Kollhorst, Hellen L. Temme, Nadine Wentzell, Ulrike Haug
-
The Safety and Efficacy of Quadruple Ultra-Low-Dose Combination (Quadpill) for Hypertension Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-30 Mohamed Abuelazm, Shafaqat Ali, Othman Saleh, Amr Badr, Obieda Altobaishat, Majd M. AlBarakat, Aya Aboutaleb, Abdelmonem Siddiq, Basel Abdelazeem
-
Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-26 Marwan Sheikh-Taha, Holly L. Clark, R. Monroe Crawley
Background The use of activated prothrombin complex concentrate (aPCC) to treat direct oral anticoagulant (DOAC)-associated bleeding is off-label and clinical experience is limited. Objectives We aimed to assess the efficacy and safety of aPCC in reversing the anticoagulant effect of apixaban and rivaroxaban in patients presenting with major bleeding. Methods A retrospective cohort study of adult non-randomized
-
Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-27 Yugo Chisaki, Hajime Nakano, Juna Minamide, Yoshitaka Yano
-
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-19 Marion Anliker-Ort, Jasper Dingemanse, Luboš Janů, Priska Kaufmann
-
Economic Evaluation of Rotavirus Vaccination in Children Aged Under Five Years in South Africa Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-13 Ahmed Mohy, Nicola Page, Welekazi Boyce, Jorge A. Gomez
-
A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-05 Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara, Aya Kuwata, Yumiko Matsuo, Ryuji Kubota
-
Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence Clin. Drug Investig. (IF 3.2) Pub Date : 2023-10-04 Jeffrey Kaplan, Anca Askanase, David Chu, Abdul Abdellatif, Dhiman Basu, Mehdi Mirsaeidi
-
Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-27 Shuang Xia, Jia-ting Ma, Emanuel Raschi, Rui Ma, Bi-kui Zhang, Linna Guo, Yoshihiro Noguchi, Mayur Sarangdhar, Hui Gong, Miao Yan
-
Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-22 Nicola Ughi, Davide Paolo Bernasconi, Francesca Del Gaudio, Armanda Dicuonzo, Alessandro Maloberti, Cristina Giannattasio, Paolo Tarsia, Giovanna Travi, Francesco Scaglione, Fabrizio Colombo, Michaela Bertuzzi, Antonella Adinolfi, Maria Grazia Valsecchi, Claudio Rossetti, Oscar Massimiliano Epis
-
Effectiveness of Dupilumab for Chronic Prurigo in Chinese Patients: A Real-World Case Series Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-17 Lu Wei, Mengting Yin, Xu Yang, Jiaying Chen, Ruimiao Wu, Heng Yang, Xia Dou
-
Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers. Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-16 Luigi Gargiulo,Luciano Ibba,Mario Valenti,Diego Orsini,Antonio Cristaudo,Pasquale Frascione,Antonio Costanzo,Alessandra Narcisi
-
Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-08 Bulent Enis Sekerel, Haylene Nell, Istvan Laki, Tatiana Pak, Edgar Contreras, Adam Kolarz, Peter D’Andrea, Volkan Manga, Monish Jain, Soniya Vaidya, Michele Valentin, Biswajit Sen
-
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-07 Johan A. Maertens, Galia Rahav, Dong-Gun Lee, Shariq Haider, Isabel Cristina Ramirez-Sanchez, Nikolai Klimko, Alfredo Ponce-de-León, Seongah Han, Rebecca Wrishko, Gregory A. Winchell, Anjana Grandhi, Hetty Waskin
-
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies Clin. Drug Investig. (IF 3.2) Pub Date : 2023-09-04 Vinicius L. Ferreira, Felipe F. Mainka, Astrid Wiens, Roberto Pontarolo
-
Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-31 Woo-young Shin, Hye Jun Lee, Jung-ha Kim
-
Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-29 Olivier Nicolas, Patricia Moliner, Patrick Soubayrol, Olivier Vitse, Sebastien Roy, Marie-José Cabanis, Tim Turner, Sylvie Klieber, Stephane Muccio, Catherine Arabeyre, Priscilla Brun
-
Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-24 Héctor Corominas, David Young, J. R. Fraser Cummings, Yoram Bouhnik, Alessandro Armuzzi, Diamant Thaci, Jihyun Kim
-
OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-22 Yu Bagger, William R. Ravis, Geoff Harris, Stan Bukofzer
-
Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-18 Ivan D. Nguyen, Evan S. Sinnathamby, Joseph Mason, Bretton Urban, Elisa E. Neuchat, Danielle M. Wenger, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye
Avacopan is a relatively novel drug with complement antagonizing properties, and it has demonstrated promising outcomes in treating antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This review article seeks to investigate the current standard of care for ANCA vasculitis with the combination of avacopan. The current standard therapy involves the usage of daily corticosteroids in
-
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-18 Luis Fein, Nicolas Lazaretti, Yamil López Chuken, J. Rogelio González Ramírez Benfield, Max S. Mano, Jose Lobaton, Ernesto Korbenfeld, Fernanda Damian, Dongrui R. Lu, Ave Mori, Shem J. Patyna, Sandra Franco
Background and Objectives Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2−) advanced breast cancer (ABC). The objectives of this expanded access trial were to provide palbociclib in combination with letrozole to patients with HR+/HER2− ABC in Argentina
-
Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-05 Shijie Lu, Yake Lou, Yi Rong, Zirui Huang, Xiaodan Lin, Junying Chen, Kongjia Luo
-
Does Opioid Use Disorder Matter for Health Care Utilization Among Lung Cancer Patients? Evidence from U.S. Hospitals During 2016–2020 Clin. Drug Investig. (IF 3.2) Pub Date : 2023-08-04 Jeong-Hui Park, Sun Jung Kim, Lily Grajeda, Alexiya Ramirez, Jongwha Chang
-
Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits? Clin. Drug Investig. (IF 3.2) Pub Date : 2023-07-28 Gabriella Chauca Strand, Naimi Johansson, Niklas Jakobsson, Carl Bonander, Mikael Svensson
-
Evaluating the Association of Montelukast Use on Neuropsychiatry-Related Healthcare Utilization and Depression in COVID-19-Hospitalized Veterans: A Nationwide VA Observational Cohort Study Clin. Drug Investig. (IF 3.2) Pub Date : 2023-07-27 Tanvi Patil, Jasper Jade Raguindin, Michelle Radtke, Joseph Smigiel, Natalie Savona, Bush Kavuru, Anuradha Sekhri
-
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence Clin. Drug Investig. (IF 3.2) Pub Date : 2023-07-21 Inês Soares de Pinho, Paulo Luz, Lucy Alves, Raquel Lopes-Brás, Vanessa Patel, Miguel Esperança-Martins, Lisa Gonçalves, Ritas Freitas, Diana Simão, Maria Roldán Galnares, Isabel Fernandes, Silvia Artacho Criado, Salvador Gamez Casado, Jose Baena Cañada, Isabel M. Saffie Vega, João G. Costa, Ana S. Fernandes, Rita Teixeira de Sousa, Luís Costa
-
Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial. Clin. Drug Investig. (IF 3.2) Pub Date : 2023-07-20 Amber van Broekhoven,John W Eikelboom,Stefan M Nidorf,Arend Mosterd,Jan H Cornel,
-
Association Between Migraine and Ischemic Cardio-Cerebrovascular Disease (CCVD) and Effects of Triptans and Ergotamine on the Risk of Ischemic CCVD in Patients with Migraine in the Korean NHIS-HEALS Cohort Clin. Drug Investig. (IF 3.2) Pub Date : 2023-07-17 Yonghwan Kim, Sang-Jun Shin, Jae-woo Lee, Ye-Seul Kim, Hyo-Sun You, Joungyoun Kim, Hee-Taik Kang